Loading...

Zynerba Pharmaceuticals, Inc.

ZYNE•NASDAQ
Healthcare
Drug Manufacturers - Specialty & Generic
$1.30
$0.03(2.36%)

Zynerba Pharmaceuticals, Inc. (ZYNE) Stock Overview

Explore Zynerba Pharmaceuticals, Inc.’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

B

Score: 61.6/100

Key Financials

Market Cap70.1M
P/E Ratio-1.59
EPS (TTM)$-0.79
ROE-0.59%

AI Price Forecasts

1 WeekN/A
1 MonthN/A
3 MonthsN/A
1 Year Target$0.16

ZYNE Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of Zynerba Pharmaceuticals, Inc. (ZYNE) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

Our forecasting models predict significant price movements, with a 12-month target of $0.16.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -1.59 and a market capitalization of 70.1M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

Stats data is not available for ZYNEStats details for ZYNE are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.
Analyst Recommendations data is not available for ZYNEAnalyst Recommendations details for ZYNE are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Company Profile

Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. The company focuses on developing pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. It is developing Zygel, a pharmaceutically-produced cannabidiol formulated as a permeation-enhanced gel for transdermal delivery. The company was formerly known as AllTranz, Inc. and changed its name to Zynerba Pharmaceuticals, Inc. in August 2014. Zynerba Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Devon, Pennsylvania.

CEO

Mr. Armando Anido MBA

Employees

25

Headquarters

80 West Lancaster Avenue, Devon, PA

Founded

2015

Frequently Asked Questions

;